Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: An echocardiographic substudy of the randomized controlled central trial

Transplantation

Volumn 97, Issue 2, 2014, Pages 184-188

  Murbraech, Klaus ^a   Holdaas, Hallvard ^a   Massey, Richard ^a   Undset, Liv H ^b   Aakhus, Svend ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Baerum County Hospital   (Norway)

Author keywords

Calcineurin inhibitor; Cardiac function; Cardiovascular disease; Cyclosporine; Echocardiography; Everolimus; Immunosuppression; Kidney transplantation; Renal transplant recipients

Indexed keywords

ADULT; AGED; CALCINEURIN; DIASTOLE; ECHOCARDIOGRAPHY; FEMALE; HEART; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; SYSTOLE;

EID: 84895139839     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182a92728     Document Type: Review

References (28)

1. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82: 603.
2. Cosio FG, Hickson LJ, Griffin MD, et al. Patient survival and cardiovascular risk after kidney transplantation: The challenge of diabetes. Am J Transplant 2008; 8: 593.
3. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024.
4. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071.
5. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217.
6. Paoletti E, Specchia C, Di Maio G, et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: A 10 year survey. Nephrol Dial Transplant 2004; 19: 1829.
7. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334.
8. Rigatto C, Foley R, Jeffery J, et al. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: Prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003; 14: 462.
9. Raichlin E, Chandrasekaran K, Kremers WK, et al. Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft. Transplantation 2008; 86: 1395.
10. Paoletti E, Amidone M, Cassottana P, et al. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: A 1-year nonrandomized controlled trial. Am J Kidney Dis 2008; 52: 324.
11. Paoletti E, Marsano L, Bellino D, et al. Effect of everolimus on left ventricular hypertrophy of De novo kidney transplant recipients: A 1 year, randomized, controlled trial. Transplantation 2012; 93: 503.
12. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557.
13. Jardine AG. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int 2005; 18: 379.
14. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: A systematic review. Drugs 2007; 67: 1167.
15. Mjornstedt L, Sorensen SS, von Zur Muhlen B, et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: A randomized trial in kidney transplantation. Am J Transplant 2012; 12: 2744.
16. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165.
17. Mourer JS, Ewe SH, Mallat MJ, et al. Late calcineurin inhibitor withdrawal prevents progressive left ventricular diastolic dysfunction in renal transplant recipients. Transplantation 2012; 94: 721.
18. Vitko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in De novo renal transplant recipients. Transplantation 2004; 78: 1532.
19. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)- based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036.
20. Gao XM,Wong G,Wang B, et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens 2006; 24: 1663.
21. McMullen JR, Sherwood MC, Tarnavski O, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004; 109: 3050.
22. Siedlecki AM, Jin X, Muslin AJ. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 2009; 75: 800.
23. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010; CD007893.
24. Hoorn EJ, Walsh SB, McCormick JA, et al. Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 2012; 25: 269.
25. Gottdiener JS, Bednarz J, Devereux R, et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 2004; 17: 1086.
26. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiographys Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440.
27. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986; 57: 450.
28. Gjesdal O, Hopp E, Vartdal T, et al. Global longitudinal strain measured by two-dimensional speckle tracking echocardiography is closely related to myocardial infarct size in chronic ischaemic heart disease. Clin Sci (Lond) 2007; 113: 287.